Navigation Links
Micromet to Present at the Cowen Health Care Conference on March 17, 2009
Date:3/6/2009

homa. Micromet is developing blinatumomab in collaboration with MedImmune, LLC, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... CA. (PRWEB) , ... August 26, 2015 , ... ... conferences to develop new business relationships with local sponsors in southern California. The Clinical ... facilitate their drug development processes and regulatory pathways., , ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... lesions are cancerous is described by University of Illinois researchers in the ... and photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ...
(Date:8/25/2015)... (PRWEB) , ... August 25, 2015 , ... One of ... -based Resilinc Corp., Bindiya Vakil, has been on a mission for the ... impact on global supply chain operations - from the two massive explosions that occurred ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... Senetek PLC,(OTC Bulletin Board: SNKTY), a Life Sciences ... science of healthy aging, today,announced an agreement with the ... in Poznan, Poland for the exclusive rights to a ... technology for,the potential use against a broad range of ...
... International,Corporation (Nasdaq: PRXL ), a leading ... has been named the "Best Contract,Research Organization (CRO)" ... to PAREXEL at the fourth annual Scrip Awards ... The Scrip Awards are designed to,celebrate innovation and ...
... 12 The following letter is being released by CEL-SCI ... , Dear Fellow Shareholders: , ... important news for CEL-SCI Corporation and its shareholders. First, the ... reference to the "cancer burden" wrote that "the global burden doubled ...
Cached Biology Technology:Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology 2PAREXEL Receives Best CRO Award from Scrip 2PAREXEL Receives Best CRO Award from Scrip 3PAREXEL Receives Best CRO Award from Scrip 4CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Park, MD (July 27, 2010) -- Drug delivery inside ... a maze of aqueous solutions, lipid membranes, and barriers ... reported in the American Institute of Physics publication the ... model that accurately predicts the hydration free energy (HFE) ...
... Park, MD (July 27, 2010) -- Fluids experts writing ... is published by the American Institute of Physics, are ... accurately probe the properties of turbulence near walls. High-Reynolds-number ... in aeronautics, naval applications, energy conversion processes, manufacturing, mixing ...
... fish scientist has received the Robert H. Gibbs, Jr. ... knowledge of fish diversity. The honor to Dr. ... the Ichthyology Department, was announced earlier this month in ... Society of Ichthyologists and Herpetologists. The Gibbs award is ...
Cached Biology News:
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
Biology Products: